Arterial wall chondroitin sulfate proteoglycans: Diverse molecules with distinct roles in lipoprotein retention and atherogenesis

Current Opinion in Lipidology

Volumn 12, Issue 5, 2001, Pages 477-487

  Williams, K J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; DECORIN; LIPOPROTEIN; PROTEOCHONDROITIN SULFATE; VERSICAN;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN MODIFICATION; REVIEW;

ANIMALS; AORTA; ARTERIOSCLEROSIS; CHOLESTEROL; HUMANS; LIPOPROTEINS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PROTEOCHONDROITIN SULFATES;

EID: 0034769771     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200110000-00002     Document Type: Review

References (164)

1. The response-to-retention hypothesis of early atherogenesis
2. The response-to-retention hypothesis of atherogenesis reinforced
3. Atherosclerosis: An inflammatory disease
4. The relationship between plasma and tissue lipids in human atherosclerosis
5. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries
6. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis
7. Interaction of native and modified low-density lipoproteins with extracellular matrix
8. Cell-surface heparan sulfate proteoglycans: Dynamic molecules mediating ligand catabolism
9. Distribution of sulfated mucopolysaccharides in invertebrates
10. Demonstration of glycosaminoglycans in Caenorhabditis elegans
11. Proteoglycans of the extracellular environment: Clues from the gene and protein side offer novel perspectives in molecular diversity and function
12. Leucine-rich repeat glycoproteins of the extracellular matrix
13. Ultrastructural localization of microfibrillar fibulin-1 and fibulin-2 during heart development indicates a switch in molecular associations
14. The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding
15. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican
16. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety
17. Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues
18. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4
19. Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype
20. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus
21. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque
22. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling
23. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts
24. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin
25. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model
26. Smooth muscle cell expression of extracellular matrix genes after arterial injury
27. Effect of TGF-beta(1) antisense S. oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries
28. Myofibroblast involvement in glycosaminoglycan synthesis and lipid retention during coronary repair
29. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells
30. Tenascin: cDNA cloning and induction by TGF-beta
31. Alternative splicing products of the tenascin gene distinguish rat liver fat storing cells from arterial smooth muscle cells and skin fibroblasts
32. The emerging role of transforming growth factor-beta in kidney diseases
33. Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells
34. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican
35. Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycan generated by alternative splicing
36. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5
37. The human decorin gene: Intron-exon organization, discovery of two alternatively spliced exons in the 5′ untranslated region, and mapping of the gene to chromosome 12q23
38. Atherosclerosis: Cell biology and lipoproteins
39. Molecular cloning and characterization of human keratan sulfate Gal-6-sulfotransferase
40. Human chondroitin 6-sulfotransferase: Cloning, gene structure, and chromosomal localization
41. Molecular cloning and expression of human chondroitin 6-sulfotransferase
42. Functional expression and genomic structure of human chondroitin 6-sulfotransferase
43. Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase
44. Molecular cloning and expression of two distinct human chondroitin 4-O-sulfotransferases that belong to the HNK-1 sulfotransferase gene family
45. Molecular cloning, expression, and chromosomal mapping of human chondroitin 4-sulfotransferase, whose expression pattern in human tissues is different from that of chondroitin 6-sulfotransferase
46. Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans
47. Cloning and expression of a proteoglycan UDP-galactose:β-xylose β1,4-galactosyltransferase I. A seventh member of the human β4-galactosyltransferase gene family
48. Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans
49. Expression cloning and characterization of NSIST, a novel sulfotransferase expressed by a subset of neurons and postsynaptic targets
50. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions
51. 125I-tyramine cellobiose-labeled low density lipoprotein is greater in the atherosclerosis-susceptible region of White Carneau pigeon aorta and further enhanced once atherosclerotic lesions develop
52. Lipoproteins containing apo B extracted from human aortas. Structure and function
53. Development of the lipid-rich core in human atherosclerosis
54. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells
55. Aggregation and fusion of modified low density lipoprotein
56. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins
57. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins
58. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH: Implications for atherosclerotic lesion development
59. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix
60. Sphingomyelinase (SMase) transgenic and knockout mice: Direct evidence that SMase is atherogenic in vivo
61. Human serum lipoproteins. II. Some effects of their intravenous injection in rats
62. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue
63. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells
64. Arterial wall proteoglycans: Biological properties related to pathogenesis of atherosclerosis
65. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lippprotein and lipoprotein(a) retention and macrophage foam cell formation
66. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells
67. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex
68. Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL). Prolonged cell-surface contact during which LDL-cholesteryl ester hydrolysis exceeds LDL protein degradation
69. Role of extracellular retention of low density lipoproteins in atherosclerosis
70. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocytes/macrophages
71. Proteoglycans and lipoproteins in atherosclerosis
72. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL
73. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction
74. Macrophage-released proteoglycans enhance LDL aggregation: Studies in aorta from apolipoprotein E-deficient mice
75. 2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity
76. Proteolysis and fusion of low density lipoprotein particles strengthen their binding to human aortic proteoglycans
77. Identification of the principal proteoglycan-binding site in LDL. A single point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding
78. Engineering non-atherogenic low density lipoproteins: Direct evidence for the 'Response-to-Retention' hypothesis of atherosclerosis
79. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Colocalization of biglycan with apolipoproteins
80. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta
81. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme
82. Expression and localization of the proteoglycan decorin during the progression of cholesterol induced atherosclerosis in Japanese quail: Implications for interaction with collagen type I and lipoproteins
83. 2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans
84. Decorin links low-density lipoproteins (LDL) to collagen: A novel mechanism for retention of LDL in the atherosclerotic plaque
85. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL
86. Decorin-type I collagen interaction. Presence of separate core protein-binding domains
87. Ultrastructure of early lipid accumulation in ApoE-deficient mice
88. Interaction of low density lipoproteins with human aortic elastin
89. The synthesis of a family of structurally related proteoglycans in fibroblasts is differently regulated by TGF-beta
90. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells
91. Stimulation of human arterial smooth muscle cell chondroitin sulfate proteoglycan synthesis by transforming growth factor-beta
92. Interleukin-1 upregulates decorin production by arterial smooth muscle cells
93. Subendothelial proteoglycan synthesis and transforming growth factor beta distribution correlate with susceptibility to atherosclerosis
94. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties
95. Proteoglycan synthesis in fetal tendon is differentially regulated by cyclic compression in vitro
96. Effects of shear stress on glycosaminoglycan synthesis in vascular endothelial cells
97. Glycosaminoglycan synthesis in the rat articular disk in response, to mechanical Stress
98. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells
99. Effect of hypoxia and hypoxia/reoxygenation on proteoglycan metabolism by vascular smooth muscle cells
100. Effects of intermittent and continuous hypoxia on the aortic wall in rabbits
101. The effect of hypoxia on the synthesis of collagen and glycosaminoglycans by cultured pig aortic endothelium
102. Effect of hypoxia on the synthesis of glycosaminoglycans and collagen by rabbit aortic smooth muscle cells in culture
103. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins
104. Complement-activated vascular smooth muscle cells secrete proteoglycans that have greatly increased LDL affinity
105. The role of C5a and antibody in the release of heparan sulfate from endothelial cells
106. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: Evidence for proteolysis of cell-surface molecules
107. Albuminuria reflects widespread vascular damage. The Steno hypothesis
108. Angiotensin-II is a major mediator of diabetes-induced suppression of heparan sulfate proteoglycan assembly in key organs involved in the acclerated atherosclerosis of diabetes mellitus
109. Complement and arteriosclerosis
110. On the reduced atherogenic effect of cholesterol feeding in rabbits with congenital complement (C6) deficiency
111. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits
112. Analysis of complement C3 activation products in human atherosclerotic lesions
113. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
114. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells
115. Low-density lipoprotein binding affinity of arterial chondroitin sulfate proteoglycan variants modulates cholesteryl ester accumulation in macrophages
116. Specificity of the low density lipoprotein-glycosaminoglycan interaction
117. The binding of chondroitin 6-sulfate to plasma low density lipoprotein
118. A competitive assay of lipoprotein: Proteoglycan interaction using a 96-well microtitration plate
119. Distinct synthetic and structural characteristics of proteoglycans produced by cultured artery smooth muscle cells of atherosclerosis-susceptible pigeons
120. Co-localization of aortic apolipoprotein B and chondroitin sulfate in an injury model of atherosclerosis
121. Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: Geographic relationship to vessel wall proteoglycans
122. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4
123. Purification and N-terminal amino acid sequence of a chondroitin sulphate/dermatan sulphate proteoglycan isolated from intima/media preparations of human aorta
124. Proteoglycan synthesis in normotensive and spontaneously hypertensive rat arteries in vitro
125. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: Correlation to patency
126. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta
127. Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans
128. Negative regulation of transforming growth factor-β by the proteoglycan decorin
129. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis
130. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease
131. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
132. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: Reversal by decorin
133. Biosynthesis and interactions of small chondroitin/dermatan sulphate proteoglycans
134. Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen
135. Selective inactivity of TGF-beta/decorin complexes
136. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity
137. Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation
138. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis
139. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats
140. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases
141. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex
142. Recombinant decorin glycoforms. Purification and structure
143. Eukaryotic expression of recombinant biglycan. Post-translational processing and the importance of secondary structure for biological activity
144. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q
145. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL
146. Immunoglobulin deposition in atherosclerotic aortocoronary saphenous vein grafts
147. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility
148. Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen
149. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding
150. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells
151. Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth
152. Versican
153. Over-expression of the chondroitin sulphate proteoglycan versican is associated with defective neural crest migration in the Pax3 mutant mouse (splotch)
154. A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican
155. Versican interacts with chemokines and modulates cellular responses
156. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44
157. Neuronal cell adhesion, mediated by the heparin-binding neuroregulatory factor midkine, is specifically inhibited by chondroitin sulfate E. Structural and functional implications of the over-sulfated chondroitin sulfate
158. Versican/PG-M isoforms in vascular smooth muscle cells
159. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice
160. Disruption of the mouse chondroitin 6-sulfotransferase gene
161. Genetic modification of arterial matrix in vivo substantially alters the development of early atherosclerosis: The decorin null mouse
162. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme
163. Hyaluronan is not just a goo!
164. Variation is the spice of life